Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Lehnick

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
BMC Cancer|August 12, 2025
Adverse drug events of immune checkpoint inhibitors - a retrospective, descriptive real-world data analysisLauris Annatha Mariam Auch, Chloé Sieber, Dirk Lehnick, et al.
British Journal of Pharmacology|July 12, 2025
SGLT2 inhibitors and their influence on iron metabolism in the context of inflammationHelene G Meyer, Chiara Tinner, Chloé Sieber, et al.
Swiss Medical Weekly|January 21, 2025
Economic evaluation in the treatment of unruptured intracranial aneurysms in the Swiss healthcare system: a retrospective cost evaluationUlf C Schneider, Stephan Bohlhalter, Florian Wüthrich, et al.
Scientific Reports|July 27, 2025
Association between nitric oxide treatment and intraventricular hemorrhage among extremely preterm neonates in Switzerland, 2012-2020Dominik Dahinden, Dirk Lehnick, Mark Adams, et al.
Pharmacology Research & Perspectives|August 17, 2019
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjectsKarsten Roth, Dirk Lehnick, Hendrik Wessels, et al.
Pharmacology Research & Perspectives|August 17, 2019
Pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjectsHendrik Wessels, Dirk Lehnick, Josef Höfler, et al.
Frontiers in Oncology|December 20, 2024
Cutaneous adverse events due to checkpoint inhibitors - a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022Clara Furrer-Matcau, Chloé Sieber, Dirk Lehnick, et al.
The Journal of Laryngology and Otology|May 16, 2024
Rating the aesthetic results after auricular reconstructive surgery for congenital aural atresia with microtiaNjima Schläpfer, Livia Papp, Dirk Lehnick, et al.
Frontiers in Pediatrics|August 9, 2021
Reduction of Duration of Antibiotic Therapy for Suspected Early-Onset Sepsis in Late-Preterm and Term Newborns After Implementation of a Procalcitonin-Guided Algorithm: A Population-Based Study in Central SwitzerlandJennifer Zihlmann-Ji, Christian Braun, Michael Buettcher, et al.
Translational Gastroenterology and Hepatology|August 23, 2021
What are the participants' perspective and the system-based impact of a standardized, inter-professional morbidity/mortality-conferences in a children's hospital?Martin Stocker, Philipp Szavay, Birgit Wernz, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
BMC Cancer|August 12, 2025
Adverse drug events of immune checkpoint inhibitors - a retrospective, descriptive real-world data analysisLauris Annatha Mariam Auch, Chloé Sieber, Dirk Lehnick, et al.
British Journal of Pharmacology|July 12, 2025
SGLT2 inhibitors and their influence on iron metabolism in the context of inflammationHelene G Meyer, Chiara Tinner, Chloé Sieber, et al.
Swiss Medical Weekly|January 21, 2025
Economic evaluation in the treatment of unruptured intracranial aneurysms in the Swiss healthcare system: a retrospective cost evaluationUlf C Schneider, Stephan Bohlhalter, Florian Wüthrich, et al.
Scientific Reports|July 27, 2025
Association between nitric oxide treatment and intraventricular hemorrhage among extremely preterm neonates in Switzerland, 2012-2020Dominik Dahinden, Dirk Lehnick, Mark Adams, et al.
Pharmacology Research & Perspectives|August 17, 2019
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjectsKarsten Roth, Dirk Lehnick, Hendrik Wessels, et al.
Pharmacology Research & Perspectives|August 17, 2019
Pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjectsHendrik Wessels, Dirk Lehnick, Josef Höfler, et al.
Frontiers in Oncology|December 20, 2024
Cutaneous adverse events due to checkpoint inhibitors - a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022Clara Furrer-Matcau, Chloé Sieber, Dirk Lehnick, et al.
The Journal of Laryngology and Otology|May 16, 2024
Rating the aesthetic results after auricular reconstructive surgery for congenital aural atresia with microtiaNjima Schläpfer, Livia Papp, Dirk Lehnick, et al.
Frontiers in Pediatrics|August 9, 2021
Reduction of Duration of Antibiotic Therapy for Suspected Early-Onset Sepsis in Late-Preterm and Term Newborns After Implementation of a Procalcitonin-Guided Algorithm: A Population-Based Study in Central SwitzerlandJennifer Zihlmann-Ji, Christian Braun, Michael Buettcher, et al.
Translational Gastroenterology and Hepatology|August 23, 2021
What are the participants' perspective and the system-based impact of a standardized, inter-professional morbidity/mortality-conferences in a children's hospital?Martin Stocker, Philipp Szavay, Birgit Wernz, et al.
Pageof 7